1. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019) Authors: Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Ma... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019) Authors: Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Ma... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial. (15th August 2020) Authors: Atkin, Catherine; Iqbal, Gulnaz; Planche, Tim; Pratt, Guy; Yong, Kwee; Wood, Jill; Raynes, Kerry; Low, Eric; Higgins, Helen; Neal, Richard D.; Dunn, Janet; Drayson, Mark T; Bowcock, Stella Journal: British journal of haematology Issue: Volume 192:Number 6(2021) Page Start: 997 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Issue 12 (December 2019) Authors: Drayson, Mark T; Bowcock, Stella; Planche, Tim; Iqbal, Gulnaz; Pratt, Guy; Yong, Kwee; Wood, Jill; Raynes, Kerry; Higgins, Helen; Dawkins, Bryony; Meads, David; Hulme, Claire T; Monahan, Irene; Karunanithi, Kamaraj; Dignum, Helen; Belsham, Edward; Neilson, Jeff; Harrison, Beth; Lokare, Anand; Cam... Journal: Lancet oncology Issue: Volume 20:Issue 12(2019) Page Start: 1760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗